About to begin a phase 2b/3 multinational study of Ifenprodil
Algernon Pharmaceuticals is a drug repurposing company. They’re a phase 2 clinical stage company advancing a drug called Ifenprodil for idiopathic pulmonary fibrosis, but also as a potential therapeutic for COVID-19.
Moreover, Algernon is about to begin a phase 2b/3 multinational study of Ifenprodil for COVID-19. Further, the study will be 150 patients. “We hope to enroll our 150 patients on a very short time period and see if we have data showing that Ifenprodil can reduce the severity and duration of a COVID-19 infection,” says CEO, Christopher Moreau.
Ifenprodil is a generic Sanofi neurological drug. It was developed in the 1970’s and is currently approved for use in South Korea and Japan.
“In the independent study for H5N1 in animals, Ifenprodil dramatically improved mortality by 40 percent. We decided to explore Ifenprodil for COVID and we hope we would see a similar effect in COVID patients reducing the severity and duration of a COVID-19 infection”, says Moreau.
About Algernon Pharmaceuticals
Algernon is a drug re-purposing company. They investigate safe, already approved drugs for new disease applications. They then move them efficiently and safely into new human trials. After, they develop new formulations and seeking new regulatory approvals in global markets. Algernon specifically investigates compounds that have never been approved in the U.S. or Europe to avoid off label prescription writing.
Their business model is to take safe approved genericized drugs and screen them in globally accepted animal models for new diseases. The Company then files new intellectual property rights. Next, they efficiently move them into off label phase II trials in the country where they were originally approved. Once a signal is established in a human trial, the company will begin to advance the repurposed drug through a US FDA registration.
For more information on Algernon Pharmaceuticals Inc. (CSE: AGN, OTCQB: AGNPF) please fill out the form below.